Twinbeech Capital LP Sage Therapeutics, Inc. Transaction History

Twinbeech Capital LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $711,949 - $1.2 Million	-67,292 Reduced 63.84%	38,114 $413,000
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $1.03 Million - $1.49 Million	55,468 Added 111.07%	105,406 $1.98 Million
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $853,939 - $1.11 Million	49,938 New	49,938 $1.08 Million
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $3.35 Million - $4.9 Million	82,316 Added 628.32%	95,417 $4.49 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $488,274 - $610,113	13,101 New	13,101 $549,000
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $428,266 - $591,200	15,562 New	15,562 $503,000
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $737,442 - $1.05 Million	-18,317 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $1.01 Million - $1.45 Million	18,317 New	18,317 $1.04 Million
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $190,215 - $561,843	-7,274 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $437,749 - $1.13 Million	7,274 New	7,274 $525,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.